A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Early Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- David Bushnell
- Target Recruit Count
- 24
- Registration Number
- NCT06148636
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- David Bushnell
- Registration Number
- NCT04614766
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Early Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- David Bushnell
- Target Recruit Count
- 20
- Registration Number
- NCT03044977
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Combination Targeted Radiotherapy in Neuroendocrine Tumors
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-06
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- David Bushnell
- Target Recruit Count
- 2
- Registration Number
- NCT01099228
- Locations
- 🇺🇸
Department of Veteran Affairs Medical Center, Iowa City, Iowa, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
© Copyright 2024. All Rights Reserved by MedPath